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AbstrACt
Introduction Abdominal aortic calcification (AAC) is 
associated with low bone mass and increased fracture 
risk. Two previous meta-analyses have investigated the 
association between AAC and fracture. However, these 
meta-analyses only identified articles until December 
2016, undertook limited searches and did not explore 
potential sources of between-study heterogeneity. We aim 
to undertake a sensitive and comprehensive assessment of 
the relationship between AAC, bone mineral density (BMD) as 
well as prevalent and incident fractures.
Methods We will search MEDLINE, EMBASE, Web of 
Science core collection and Google Scholar (top 200 articles 
sorted by relevance) from their inception to 1 June 2018. 
Reference lists of included studies and previous systematic 
reviews will be hand searched for additional eligible studies. 
Retrospective and prospective cohort studies (cross-
sectional, case–control and longitudinal) reporting the 
association between AAC, BMD and fracture at any site will 
be included. At least two investigators will independently: 
(A) evaluate study eligibility and extract data, with a third 
investigator to adjudicate when discrepancies occur, (B) 
assess study quality by the Newcastle-Ottawa Scale for 
each cohort/study. The meta-analysis will be reported in 
adherence to the Meta-analysis of Observational Studies in 
Epidemiology criteria. AAC will be grouped as either: (1) AAC 
present or absent, (2) AAC categorised as ‘low’ (referent—
lowest reported group) versus ‘high’ (all other groups) or 
(3) dose–response when AAC was assessed in ≥3 groups. 
Where primary event data were reported in individual 
studies, pooled risk differences and risk ratios with 95% CI 
will be calculated, from which, a summary estimate will 
be determined using DerSimonian-Laird random effects 
models. For the AAC and BMD pooled analyses, estimates 
will be expressed as standardised mean difference with 
95% CI. We will examine the likelihood of publication bias 
and where possible, investigate potential reasons for 
between-study heterogeneity using subgroup analyses and 
meta-regression.
Ethics and dissemination The study will be submitted 
to a peer- reviewed journal and disseminated via research 
presentations. 
PrOsPErO registration number CRD42018088019.
IntrOduCtIOn  
Vascular and bone diseases are both chronic 
age-related disease that share many common 
dietary and lifestyle risk factors and cause 
considerable morbidity and mortality.1 
Atherosclerotic lesions in the abdominal 
aorta generally begin around the major vessel 
bifurcations and branching arteries such as 
the inferior mesenteric artery and the lumbar 
arteries that supply blood and nutrients to the 
lumbar vertebrae.2 Occlusion of these vessels 
may causes ischaemia in the lumbar spine and 
may result in disc degeneration and asymp-
tomatic vertebral fractures.3 Additionally, 
the underlying processes regulating arterial 
calcification share many similarities to bone 
physiology4 and calcified atherosclerotic 
plaques release both local and systemic osteo-
chondrogenic factors that may affect regional 
and systemic bone homoeostasis.5 Conversely 
circulating levels of factors regulating bone 
homoeostasis may also regulate vascular 
strengths and limitations of this study
 ►   This study will use meta-regression to identify 
sources of heterogeneity and identify subgroups or 
subpopulations where abdominal aortic calcification 
(AAC) is more or less predictive of poorer outcomes. 
 ► To our knowledge, there has been no systematic 
review and meta-analysis that has investigated the 
association between AAC and bone mineral density 
(BMD), which is along the hypothesised causal path-
way to fracture.
 ► The main limitation of this review is that causality 
cannot be established due to the observational na-
ture of the studies.
 ► A further limitation is the differences in imaging 
modality, measurement and reporting of AAC across 
studies but we attempted to overcome this by ex-
ploring these aspects in prespecified subanalyses.
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calcifications6 with a number of studies demonstrating 
osteoporosis and bone mineral density (BMD) being a 
risk factor for cardiovascular disease (CVD).7 8 
Assessment of lateral spine images is often undertaken 
to detect prevalent vertebral fractures and has been shown 
to improve fracture prediction.9–11 These images can also 
be used to assess the degree of abdominal aortic calci-
fication (AAC). To date, there are conflicting findings 
as to whether AAC is associated with BMD and fractures 
and whether or not these associations are due to ageing, 
shared fracture risk factors or are a non-traditional 
independent fracture risk factor. Recent meta-analyses 
published in 201612 and 2017,13 looking at observational 
studies, showed that people with any or high AAC were at 
greater risk of fractures than those with no or low AAC. 
However, the previous studies by Chen and Yu12 and 
Wei et al13 only identified a limited number of articles 
due to the search strategies employed (searches found 
91 and 105 articles, respectively) and the meta-anal-
yses missed many of the known studies in the area (by 
way of example—both studies missed Wang et al.14). For 
example, our recent search identified 1561 potentially 
eligible reports. Furthermore, both meta-analyses iden-
tified unexplained moderate-high heterogeneity that 
needs to be explored further. As such uncertainty exists 
as to the importance of identifying AAC for incident frac-
ture risk, particularly with respect to AAC cut-points, types 
of fracture and potential explanations for the observed 
between-study heterogeneity. We will, therefore, under-
take a meta-analysis of studies reporting on AAC, BMD at 
any site and prevalent and incident fractures at any site.
ObjECtIvEs
1. To determine the association between AAC with BMD 
at any site.
2. To determine the association between AAC with prev-
alent fractures (cross-sectional) by reported prevalent 
fracture sites.
3. To determine the association between AAC with inci-
dent fractures by reported incident fracture sites.
4. To assess the impact of potential effect modifiers, in-
cluding aspects of clinical, methodological and statisti-
cal heterogeneity on previous published findings.
MEthOds And AnAlysIs
The systematic review and meta-analysis reported in 
adherence to the Meta-analysis of Observational Studies 
in Epidemiology reporting criteria.15
Patient and public involvement statement
There is no patient or public involved in this systematic 
review/meta-analysis.
Eligibility criteria for studies included in this review
Criteria for considering studies for review
a. Observational studies in humans. These include cohort 
(both retrospective and prospective cohort studies), 
case–control and cross-sectional studies that report eli-
gible exposure(s) and outcome(s).
b. AAC assessed by any methodology.
c. Report any BMD measure or prevalent or incident 
fracture outcome.
Exclusion criteria
a. Reviews of existing literature.
Exposure
AAC identified from either radiography, dual X-ray 
absorptiometry (DXA) machine or CT. AAC will be 
presented as:
a. AAC present or absent.
b. AAC categorised as low (referent—lowest reported 
group) versus moderate to high (all other reported 
groups combined).
c. AAC dose–response when AAC was assessed in three or 
more groups categorised as low (lowest reported cate-
gory), moderate (middle reported category[ies]) and 
high (highest reported category).
Outcomes
1. BMD (by site).
2. Prevalent fractures (by fracture site).
3. Incident fractures (by fracture site).
Cohort characteristics for meta-regression (where available)
 ► Cohort age (cohort mean).
 ► Gender (% female).
 ► Years since menopause (cohort mean).
 ► Hormone replacement therapy (%).
 ► Modality of assessing AAC (DXA, standard radiograph 
or CT).
 ► Cut-points chosen for comparison (low vs high, 
tertiles etc).
 ► Diabetes (% of cohort).
 ► Current smoker (% of cohort).
 ► History of smoking (% of cohort).
 ► Body mass index (cohort mean).
 ► Chronic kidney disease (% of cohort).
 ► History of CVD (% of cohort).
 ► Location of study (Europe, Asia-Pacific, North 
America), that is, are association consistent across 
ethnicities and nation wealth.
 ► Prevalence of CVD medication use (% of cohort).
 ► History of fracture (% of cohort).
study design
Search strategies
A comprehensive literature search within MEDLINE, Web 
of Science core collection and EMBASE databases will 
be conducted to source all possibly relevant studies for 
review, without language restriction. Google Scholar will 
be searched for the top 200 articles sorted by relevance. 
The search terms will be combined with the boolean 
‘AND’ to find all potentially relevant studies. Conference 
proceedings and abstracts will also be evaluated. A hand 
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search of reference lists of eligible studies and previous 
meta-analyses will also be undertaken. Non-English 
papers will be translated and evaluated for eligibility. If 
more than one publication of a study is retrieved, articles 
with the most up to date and complete information will 
be included, although additional unique data from all 
sources will be considered and included when relevant. 
Examples of the search strategy are shown in table 1.
Process for selecting studies
Two or more independent authors (AR, KL, MS and JRL) 
will assess retrieved citations to assess studies for eligi-
bility. Briefly, the process for selecting studies for inclu-
sion in the review and meta-analysis will be as follows: 
merge all identified records using EndNote; remove 
duplicate records of the same report; retrieve full text of 
the potentially relevant reports; link together multiple 
reports of the same study (using the first or largest 
report as the primary record and subsequent reports to 
supplement other data); examine full-text reports for 
compliance with eligibility criteria; correspond with inves-
tigators, where appropriate, to clarify study eligibility and 
request missing data; make final decisions on study inclu-
sion. Discrepancies about inclusion will be resolved via 
iteration and consensus or a third reviewer if consensus 
cannot be reached between the two reviewers. Excluded 
studies identified that may plausibly be expected to be an 
included will be reported in online supplementary data 
with a detailed explanation for the reason of exclusion.
risk of bias and quality assessment
The risk of bias for observational studies will be assessed 
using the Newcastle-Ottawa Scale (NOS). An example of 
this scale is provided in online supplementary material 
1A–D. In addition, publication bias will be assessed by 
visual inspection of a funnel plots and the Egger’s and 
Begg’s regression tests. Summary estimates of the confi-
dence placed on the evidence will be evaluated using the 
Grading of Recommendations Assessment Development 
and Evaluation (GRADE) of evidence about prognosis. 
GRADE for evidence about prognosis starts with high-
quality evidence that can then be rated down. These 
criteria are based on; (1) five domains diminishing confi-
dence (−1 for risk of bias, inconsistency, imprecision, 
indirectness and publication bias) and (2) two situations 
increasing confidence (+1 or +2 for large-very large effect 
size and a +1 for a dose–response gradient (increasing 
pooled relative risks for fractures with increasing severity 
of AAC)).16
statistical analysis and data synthesis
Analysis of outcome variables will be presented according 
to either: (1) AAC present or absent (2) AAC categorised 
as ‘low’ (referent—lowest reported group) versus ‘high’ 
(all other groups) or (3) dose–response when AAC was 
assessed in three or more groups. For the dose–response 
analysis, the lowest reported group (low AAC group) will 
be compared with the middle group(s) versus the highest 
reported AAC group (high AAC). Where data on more 
than three groups of AAC were presented the middle 
groups were combined as ‘moderate AAC’. This approach 
was selected due to many studies reporting on variable 
number of AAC groups with the majority of studies using 
different cut-points for these groupings. Data on the 
severity of AAC quantification presented as a continuous 
measure or in three or more groupings of AAC will be 
used to determine the impact of increased abdominal 
aortic calcium load on outcomes. Where primary event 
data were reported in individual studies, pooled risk 
differences and risk ratios with 95% CIs will be calculated, 
from which, a summary estimate was determined using 
Table 1 Example search strategies
Keyword MEDLINE Embase
Population=adults No search strategy No search strategy
Intervention/Test=aortic 
calcification
exp Vascular Calcification/or exp Calcinosis/
or exp Vascular Diseases/or arterial calcification.
mp or exp Arteriosclerosis/or exp Arterial 
Occlusive Diseases/or exp Aortic Diseases/
or aortic.mp or vascular calcifications.mp. 
or exp Vascular Calcification/or calcified 
atherosclerosis.mp or calcification.mp or 
calcified atherosclerotic plaque.mp or arterial 
calcium.mp or aortic calcification.mp or aorta 
calcification.mp and aort$.mp and calc$.mp
vascular calcification.mp. or exp blood vessel 
calcification/or artery calcification.mp. or exp 
artery calcification/or exp coronary artery 
disease/or exp arteriosclerosis/or calcified 
atherosclerosis.mp or arterial calcium.
mp or calcified atherosclerotic plaque.mp 
or calcification.mp or aortic calcification.
mp or aorta calcification.mp or vascular 
calcifications.mp or arteriosclerosis.mp or 
extracoronary.mp and aort$.mp and calc$.mp
Methodology=observational No search strategy No search strategy
Comparator=None No search strategy No search strategy
Outcome = bone mineral density.mp or exp Bone Density/
or Fracture.mp or Fractures.mp
bone mineral density.mp or exp bone density/
or fracture.mp or fractures.mp or exp fracture/
Additional specific filters Human Human
The reference lists of recent literature reviews and guidelines will be hand searched for possibly relevant studies.
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DerSimonian-Laird random effects models. For the AAC 
and BMD pooled analyses, estimates will be expressed as 
standardised mean difference with 95% CI. Values will 
be considered significant if the 95% CI of the point esti-
mate does not cross unity. Between-study heterogeneity 
will also be investigated by using subgroup analyses and 
the I2 statistic by study ID which quantifies inconsistency 
across studies to assess the impact of heterogeneity on 
the meta-analysis.17 18 We will evaluate for heterogeneity 
using the I2 statistic and considered the I2 thresholds 
of <25%, 25%–49%, 50%–75% and >75% to represent 
low, moderate, high and very-high heterogeneity.
subgroup analysis and investigation of heterogeneity
We will perform meta-regression of cohort characteristics 
to identify factors potentially explaining heterogeneity 
as well as performing subgroup analyses. P<0.01 will be 
considered statistically significant for subgroup anal-
yses. Preplanned subgroup analyses to explore statistical 
heterogeneity will include stratification by:
1. Subgroups based on clinical heterogeneity, for exam-
ple, disease populations (general population, diabet-
ics, chronic kidney disease, other) and age groups (<60 
years, 60–69 years and ≥70 years).
2. Methodological heterogeneity, for example, AAC as-
sessment methods (radiography, DXA or CT), thresh-
olds to define high or severe AAC, fracture reporting 
and validation.
3. Statistical heterogeneity, for example, cohort charac-
teristics (mean ages of the cohorts).
Further analyses
Where data on the severity of AAC quantification are 
presented as a continuous measure or in tertile/catego-
ries these data will be used to determine the impact of 
increased abdominal aortic calcium load on prognosis. 
Where AAC is not scored using the AAC24 scale equiva-
lent values will be relative to estimated vertebral heights 
from similar aged populations. Where AAC is assessed by 
CT the categorical low vs moderate and high AAC will be 
used.
sensitivity analysis
We will carry out sensitivity analyses for:
1. Large studies alone to establish how much they domi-
nate the results (n>500 participants).
2. Methodology—we will assess the methodological qual-
ity of studies using the NOS for assessing the quality of 
nonrandomised studies in meta-analyses (online sup-
plementary material 1). For the purpose of this sen-
sitivity analysis, we will use three categories of quality 
(good, fair or poor).
3. Studies conducted in individuals without a history of 
a prior fracture (as this is the biggest risk factor for a 
new fracture).
4. Studies conducted in high-income versus low-income 
countries.
5. Studies that included non-osteoporotic fractures (frac-
tures of the toes, fingers, face and skull fractures).
6. Study design bias comparing outcomes in cross-sec-
tional and prospective studies (given that prospec-
tive studies may also include prevalent fractures and 
BMD measurements at baseline that can be analysed 
cross-sectionally).
COnCludIng stAtEMEnt
Previous meta-analyses on this topic have a number of 
important limitations. By undertaking the preplanned 
comprehensive review and meta-analysis, we will gain 
better understanding of the relationship between AAC, 
BMD and increased fracture risk. The review will provide 
impetus for further research, diagnosis and treatment of 
this novel fracture risk factor. This review will also evaluate 
the quality of the published evidence and our confidence 
in the estimates for the meta-analysis, while identifying 
important knowledge gaps, potential sources of between-
study heterogeneity and issues with imaging, assessing or 
reporting of AAC in published studies.
Ethics and dissemination
The study will be submitted to a peer-reviewed journal 
and disseminated via research presentations.
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